Table 3 Clinical features of patients with HIV-associated Burkitt lymphoma at diagnosis with or without central nervous system involvement
Features | CNS-involvement, N (%) | Without CNS-involvement, N(%) | P |
|---|---|---|---|
Total | 8 | 33 | |
Sex | |||
Male | 8(100) | 28(84.8) | 0.563 |
Age | |||
<40 | 6 (75.0) | 14(42.4) | 0.130 |
≥40 | 2 (25.0) | 19(57.6) | |
Primary site | |||
Nodal | 5 (62.5) | 26(78.8) | 0.378 |
Extra-nodal | 3 (37.5) | 7(21.2) | |
Ann Arbor stage | |||
I-II | 0 (0) | 10(30.3) | 0.165 |
III-IV | 8 (100) | 23(69.7) | |
B symptom | |||
Presence | 8 (100) | 18(54.5) | 0.018 |
Absence | 0 (0) | 15(45.5) | |
ECOG PS | |||
0–1 | 1 (12.5) | 24(72.7) | 0.003 |
≥2 | 7 (87.5) | 9(27.3) | |
BM involvement | |||
Yes | 6 (75.0) | 13(39.4) | 0.115 |
No | 2 (25.0) | 20(60.6) | |
Bulky disease | |||
Yes | 2 (25.0) | 12(36.4) | 0.692 |
No | 6 (75.0) | 21(63.6) | |
CD4 count | |||
≤100cells/μl | 2 (25.0) | 3(9.1) | 0.246 |
>100cells/μl | 6 (75.0) | 30(90.9) | |
LDH level | |||
≤ 3x ULN | 3 (37.5) | 18(54.5) | 0.454 |
>3x ULN | 5 (62.5) | 15(45.5) | |
BL-IPI staging | |||
Low | 0(0) | 7(21.2) | 0.08 |
Intermediate | 4 (50.0) | 18(54.5) | |
High | 4 (50.0) | 8(24.2) | |
First-line treatment | |||
R-Hyper-CVAD/MA | 3 (37.5) | 10(30.3) | 0.505 |
R-DA-EPOCH | 3 (37.5) | 9(27.3) | |
DA-EPOCH | 1 (12.5) | 9(27.3) | |
Others | 1 (12.5) | 5(15.1) | |
Rituximab | |||
With | 5 (62.5) | 19(57.6) | 0.563 |
Without | 3(37.5) | 14(42.4) |